Literature DB >> 17631592

Response evaluation: beyond RECIST.

E A Eisenhauer1.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17631592     DOI： 10.1093/annonc/mdm290

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.

Authors:  Kenichiro Enooku; Ryosuke Tateishi; Fumihiko Kanai; Yuji Kondo; Ryota Masuzaki; Tadashi Goto; Shuichiro Shiina; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2011-09-21       Impact factor: 7.527

2.  Comparison of volumetric methods for tumor measurements on two and three dimensional MRI in adult glioblastoma.

Authors:  Mei-Yun Wang; Jing-Liang Cheng; Yan-Hong Han; Yong-Li Li; She-Wei Dou; Feng-Shan Yan; Da-Peng Shi
Journal:  Neuroradiology       Date:  2010-11-06       Impact factor: 2.804

3.  Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism.

Authors:  Rasha Elmghirbi; Tavarekere N Nagaraja; Stephen L Brown; Swayamprava Panda; Madhava P Aryal; Kelly A Keenan; Hassan Bagher-Ebadian; Glauber Cabral; James R Ewing
Journal:  Radiat Res       Date:  2016-12-21       Impact factor: 2.841

Review 4.  Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

Authors:  Blanca Homet Moreno; Elena Garralda Cabanas; Ricardo Hitt
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

5.  Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib.

Authors:  Xiaoqin Li; Shan Liu; Hangang Gu; Deqiang Wang
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-05       Impact factor: 4.553

6.  Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.

Authors:  Shauna L Hillman; Ming-Wen An; Michael J O'Connell; Richard M Goldberg; Paul Schaefer; Jan C Buckner; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

7.  Objective assessment of tumour response to therapy based on tumour growth kinetics.

Authors:  E Mehrara; E Forssell-Aronsson; P Bernhardt
Journal:  Br J Cancer       Date:  2011-07-26       Impact factor: 7.640

8.  MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients.

Authors:  Magdalena Lukamowicz-Rajska; Christiane Mittmann; Michael Prummer; Qing Zhong; Jens Bedke; Jörg Hennenlotter; Arnulf Stenzl; Axel Mischo; Svenja Bihr; Manuela Schmidinger; Ursula Vogl; Iris Blume; Christoph Karlo; Peter Schraml; Holger Moch
Journal:  Oncotarget       Date:  2016-11-29

9.  Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.

Authors:  Melissa C Paoloni; Anita Tandle; Christina Mazcko; Engy Hanna; Stefan Kachala; Amy Leblanc; Shelley Newman; David Vail; Carolyn Henry; Douglas Thamm; Karin Sorenmo; Amin Hajitou; Renata Pasqualini; Wadih Arap; Chand Khanna; Steven K Libutti
Journal:  PLoS One       Date:  2009-03-30       Impact factor: 3.240

10.  Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.

Authors:  Marius Horger; Ulrich M Lauer; Christina Schraml; Christoph P Berg; Ursula Koppenhöfer; Claus D Claussen; Michael Gregor; Michael Bitzer
Journal:  BMC Cancer       Date:  2009-06-28       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.